Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
PLATFORM Trial Analysis for Durvalumab Demonstrates Patient Subset Gained Radiological Response
Read More
CheckMate-577: Nivolumab Adjuvant Therapy in Patients with Resected Esophageal or GEJ Cancer Is Associated with Significant Disease-Free Survival
Read More
Retrospective Study of Nivolumab Monotherapy Treatment Lines
Read More
LEAP-005 Clinical Trial Yields Promising Efficacy and Safety Data for Patients with Gastric Cancer
Read More
CheckMate-648: Nivolumab with Ipilimumab or Chemotherapy Improves OS in Patients with Advanced Esophageal Squamous-Cell Carcinoma
Read More
DisTinGuish Part A Trial of DKN-01 plus Tislelizumab and CAPOX Results Indicate Early Activity in Patients with Advanced DKK1-High Gastroesophageal Adenocarcinoma
Read More
CheckMate-649: Survival Outcome Improved in Patients with Advanced Gastric/Esophageal Cancer Treated with Nivolumab Combined with Chemotherapy
Read More
Gastrointestinal Cancers
Health-Related Quality-of-Life Scores Higher in Patients with Advanced Gastric Cancer, Esophageal Adenocarcinoma, or Gastroesophageal Junction Cancer Receiving Nivolumab plus Chemotherapy
Read More
Gastrointestinal Cancers
First-Line Pembrolizumab plus Chemotherapy Improves Overall Survival and Progression-Free Survival in Patients with Advanced Esophageal Cancer
Read More
Gastrointestinal Cancers
Sintilimab Therapy in Patients with Previously Treated Advanced or Metastatic Gastric Cancer Demonstrates Modest Response
Read More
80
81
82
83
84
85
86
Page 83 of 199
Results 821 - 830 of 1986
